卡培他滨联合曲妥珠单抗治疗HER-2阳性转移性乳腺癌的临床研究

Clinical study of capecitabine combined with trastuzumab in treatment of Her-2 positive metastatic brerst cancer

目的 研究卡培他滨联合曲妥珠单抗治疗人表皮生长因子受体2(HER-2)阳性转移性乳腺癌的临床效果。方法 研究对象均来自2020年6月—2021年6月唐山市人民医院乳腺外科收治的75例HER-2阳性转移性乳腺癌患者,依据随机数字表法把符合条件的患者分成二组,其中对照组37例,观察组38例,对照组患者给予单独卡陪他滨药物治疗,观察组患者给予卡培他滨联合靶向药物曲妥珠单抗治疗。经系统治疗后比较对照组和观察组二组患者治疗疗效的差别情况;通过FACT-B评分比较二组乳腺癌患者生存质量情况;通过免疫功能指标CD4^(+)、CD4^(+)/CD8^(+)比较二组患者免疫功能情况;比较二组患者不良反应发生率。结果治疗后观察组患者治疗有效缓解率高于对照组;治疗后观察组患者FACT-B评分明显高于对照组;治疗后观察组患者血清CD4^(+)、CD4^(+)/CD8明显高于对照组;治疗后观察组患者出现不良反应(恶心呕吐、白细胞降低、腹泻,肝功能下降)即不良反应发生率低于对照组,以上差异均有统计学意义(均P<0.05)。结论 卡培他滨联合曲妥珠单抗治疗HER-2阳性转移性乳腺癌患者,对于提高该类患者的临床缓解率以及改善其生存质量都起到了重要作用,同时也能提高HER-2阳性转移性乳腺癌患者的一定的免疫功能,降低不良反应的发生情况。

Objective To investigate the clinical value of capecitabine combined with trastuzumab in the treatment of human epidermal growth factor receptor 2(HER-2) positive metastatic breast cancer. Methods The study subjects were all seventy-five patients with HER-2 positive metastatic breast cancer admitted to the Breast Surgery Department of Tangshan People's Hospital from June 2020 to June 2021.Eligible patients were divided into two groups according to random number table method, including seventy-five cases in the control group and thirty-eight cases in the study group.Control group was treated with caprocitabine alone, and study group was treated with capecitabine combined with trastuzumab.After systematic treatment, the difference of therapeutic efficacy between the control group and the study group was compared.The quality of life of breast cancer patients in the two groups was compared by FACT-B score.The immune function of patients in the two groups was compared by CD4^(+),CD4^(+)/CD8^(+),and the incidence of adverse reactions was compared between the two groups. Results After treatment, the effective remission rate of study group was higher than that of control group;after treatment, the FACT-B score of study group was significantly higher than that of control group;after treatment, serum CD4^(+) and CD4^(+)/CD8^(+) in study group were significantly higher than those in control group;after treatment, the incidence of adverse reactions(nausea and vomiting, leukopenia, diarrhea, decreased liver function) in study group was lower than that in control group, and all the differences were statistically significant(P<0.05). Conclusion Capecitabine combined with trastuzumab in the treatment of patients with HER-2 positive metastatic breast cancer plays an important role in improving the clinical remission rate and quality of life of these patients, and can also improve certain immune function of patients with HER-2 positive metastatic breast cancer and reduce the occurrence of adverse reactions.